Russia's sovereign wealth fund said it will sell 10 cr doses of the 'Sputnik-V' COVID-19 vaccine to Dr Reddy's Laboratories once it receives regulatory approval in India. It has also agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian drugmaker.
Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with the Indian firm. Both the trials and supply deal depend on domestic regulatory approval. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on August 26 but have yet to be completed.